<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2452">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129241</url>
  </required_header>
  <id_info>
    <org_study_id>OBS17242</org_study_id>
    <secondary_id>U1111-1265-6221</secondary_id>
    <nct_id>NCT05129241</nct_id>
  </id_info>
  <brief_title>Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector</brief_title>
  <acronym>MARS</acronym>
  <official_title>Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives:&#xD;
&#xD;
        -  To assess the effectiveness of the PRALUENT® 2 ml SYDNEY auto-injector as measured by&#xD;
           the lipid-lowering effect of alirocumab after approx. 12 weeks treatment&#xD;
&#xD;
        -  To assess the treatment satisfaction, as well as patient adherence and persistence after&#xD;
           approximately 12 weeks of treatment with the PRALUENT® 2 ml SYDNEY auto-injector&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      Safety and tolerability&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximately 12 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Weeks</target_duration>
  <primary_outcome>
    <measure>Absolute change from baseline to week 12 in low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>from baseline to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline to week 12 in low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>from baseline to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment acceptance assessed using the Injection Treatment Acceptance Questionnaire (ITAQ)</measure>
    <time_frame>week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of quality defects assessed using product complaints</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Primary Hypercholesterolaemia and Mixed Dyslipidaemia</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Patients for whom the treating physician has decided to initiate lipid-lowering treatment with the PRALUENT® 2 ml SYDNEY auto-injector, irrespective of participation in the study</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or&#xD;
        mixed dyslipidaemia and confirmed cardiovascular disease and with regular additional risk&#xD;
        factors, and/or patients with confirmed familial heterozygous hypercholesterolaemia for&#xD;
        whom the treating physician has decided to initiate lipid-lowering treatment with the&#xD;
        PRALUENT® 2 ml SYDNEY auto-injector, irrespective of participation in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary hypercholesterolaemia (heterozygous familial or non-familial) or mixed&#xD;
             dyslipidaemia AND confirmed vascular disease(*) AND other regular risk factors(**), OR&#xD;
             confirmed familial heterozygous hypercholesterolaemia&#xD;
&#xD;
          -  Documented maximum dietary and drug lipid-lowering therapy within the last 12 months&#xD;
&#xD;
          -  Inadequate reduction of low-density lipoprotein cholesterol (LDL-C) despite maximum&#xD;
             possible dietary and lipid-lowering therapy&#xD;
&#xD;
          -  The decision of the treating physician to use the PRALUENT® 2 ml SYDNEY auto-injector&#xD;
             regardless of study enrolment&#xD;
&#xD;
          -  No previous therapy with a proprotein convertase subtilisin/kexin type 9 (PCSK9)&#xD;
             inhibitor OR prior treatment with a PCSK9 inhibitor every 2 weeks (Q2W) or monthly&#xD;
             (Q4W)&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
        (*) Coronary heart disease (CHD), cerebrovascular manifestation, peripheral arterial&#xD;
        occlusive disease (PAOD)&#xD;
&#xD;
        (**) For cardiovascular events (e.g. diabetes mellitus, renal function glomerular&#xD;
        filtration rate (GFR) &lt; 60 ml/min)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned or existing pregnancy, cancer, drug or alcohol abuse, dementia, or general&#xD;
             inability to understand the content of the observational study&#xD;
&#xD;
          -  Existing treatment by lipid apheresis&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Contraindications to treatment with alirocumab (PRALUENT®) according to the SmPC&#xD;
&#xD;
          -  Current participation in a clinical study&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>contact-US@sanofi.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

